Introduction: The Paris modification of the Montreal classification for children with inflammatory bowel disease was accepted in 2011. We aimed to investigate the long-term clinical outcomes of patients diagnosed with IBD during childhood in a population-based cohort according to the Paris classification at diagnosis. 
Introduction
Inflammatory bowel disease [IBD] is a group of chronic immunemediated diseases involving the gastrointestinal tract, traditionally classified into two main subtypes: Crohn's disease [CD] and ulcerative colitis [UC] . Approximately 25% of all IBD patients are diagnosed during childhood 1 with a sustained rise in incidence over time, particularly in Western countries. 2, 3 Paediatric IBD is generally considered as more aggressive and commonly requires more intensive pharmacological and surgical treatments. 4, 5 The paediatric modification of the Montreal classification for IBD, the Paris classification, 6 emerged in 2011, in order to address gaps attributed to the dynamic features of paediatric disease phenotype, including the change in disease location and behaviour over time, and the effect of the disease on growth. The paediatric modification incorporated new sub-classifications into the Montreal framework, including a more stratified classification of age and upper gastrointestinal involvement in CD and extent of disease in UC. It also added a new category of growth delay in CD patients and enabled the classification of both stricturing and penetrating disease in the same patient.
The Paris classification further assisted in defining specific characteristics of each phenotype. For example, it was demonstrated that children younger than 10 years at diagnosis are more likely to present with isolated colonic disease and have lower rates of complicated disease at diagnosis, 7, 8 whereas patients with colonic phenotype [L2] are less likely to have upper gastrointestinal involvement or stricturing disease than patients with ileal or ileocolonic disease. 8 Nevertheless, the long-term outcomes of these phenotypes were only sparsely studied, [9] [10] [11] and the predictive properties of the Paris classification at the time of diagnosis are still controversial. Therefore, we aimed to explore long-term clinical outcomes of the specific phenotypes in paediatric onset disease, which was therefore classified according to the Paris classification in a population-based cohort at a tertiary hospital in Israel.
Materials and Methods

Patients
Data were retrieved retrospectively from structured computerised medical records of paediatric patients diagnosed with IBD between the ages 0 and 17 years [inclusive] from January 2000 to June 2016, at the Schneider Children's Medical Center of Israel which serves as both primary and tertiary centre for more than 1 million children. IBD diagnosis was based on the accepted clinical, endoscopic, and histological criteria. All patients with a minimum of 12 months of follow-up were included.
Description of variables
For each patient, data at diagnosis included demographic, anthropometric, clinical, laboratory, radiological and endoscopic variables. Disease phenotype at diagnosis was categorised according to the Paris classification. 6 For statistical analysis of the correlation between variables at diagnosis and the constructs of the Paris classification, and also for survival analysis, B2 and B3 phenotypes were grouped together for CD patients, whereas the extent category in UC patients was stratified into left-sided colitis [E1 and E2] included arthritis of all types, related skin disorders, primary sclerosing cholangitis, and uveitis. Data collected throughout the follow-up period included four main outcomes: disease flares, hospitalisations, step-up to biologic treatment, and surgical procedures. Disease flare was defined as HBI ≥ 5 and suggestive symptoms for CD, and as PUCAI ≥ 10 for UC.
Data analysis
Categorical variables were described as frequency and percentage. Continues variables were evaluated for normal distribution using histogram and Q-Q plots. Normally distributed continuous variables were presented as mean and standard deviation, and non-normally distributed continuous variables were reported as median and interquartile range [IQR] . Continuous variables were compared using analysis of variance [ANOVA], independent sample t test, KruskalWallis test, or Mann-Whitney test, as appropriate. Categorical variables were compared using the chi-square test or Fisher's exact test. Length of follow-up was evaluated using a reverse censoring method. Time to first flare, hospitalisation, surgical intervention, and biologic therapy during follow-up was described using Kaplan-Meier plots. Univariate and multivariate Cox regression was used to evaluate the crude and adjusted association between exposure and outcomes. The multivariate model included age at diagnosis, gender, all the Paris classification constructs, and other variables with a significance level of p < 0.2 at the univariate analysis. All statistical tests were twotailed, and p < 0.05 was considered as statistically significant. All statistical tests were performed using SPSS [IBM Corp., released 201;. IBM SPSS Statistics for Windows, version 24, Armonk, NY]. The study protocol was approved by the local Internal Review Board at the Rabin/Schneider Medical Center.
Results
The In the univariate analysis age category at diagnosis [< 10 years vs ≥ 10 years] was not associated with any of the variables at diagnosis except for higher frequencies of colonic phenotype and hypoalbuminaemia in the younger age group [ Table 2 ].
Disease location at diagnosis showed the most distinctive phenotypic features. L2 [isolated colonic] location was associated with higher prevalence of extraintestinal manifestations, and L1 and L3 phenotypes were associated with ASCA positivity [ Table 2 ]. Height Z-score also differed at diagnosis according to location, as patients with L3 phenotype demonstrated a significantly lower median height Z-score compared with L1 and L2 phenotypes [ Figure 1a ]. B2-3 patients were also subjected to an increased risk for early hospitalisation, with 67.5% of these patients being hospitalised after a median time of 1.3 years [95% CI 0.5-5.6] compared with B1 patients [52% hospitalisation rate, median time 7.7 years, 95% CI ASCA, anti-Saccharomyces cerevisiae antibody; 5-ASA, 5-aminosalicylic acid; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HBI, Harvey-Bradshaw Index; IBD, inflammatory bowel disease; IQR, interquartile range; PCDAI, Paediatric Crohn's Disease Activity Index; pANCA, perinuclear anti-neutrophil cytoplasmic antibodies; PUCAI, Paediatric Ulcerative Colitis Activity Index; SD, standard deviation. A1b], L4, and G phenotypes were not found to predict any of the four outcomes [data not shown].
Ulcerative colitis patients
The clinical characteristics of patients with ulcerative colitis [n = 126] at diagnosis are summarised in In comparison with S0 phenotype, severe disease [S1] was also associated with multiple clinical and biochemical variables [ Table 3 ] including lower weight Z-score, higher PUCAI score, lower haemoglobin level, lower albumin, higher CRP, and elevated ESR. S1 phenotype was also associated with an increased rate of corticosteroid treatment at diagnosis [35/37, 94.6% vs 35/86, 40.7%, p < 0.001]. In the multivariate analysis, all variables but weight Z-score maintained statistical significance [ Table 3 ].
Survival analyses of disease outcomes according to extent at diagnosis [E1-2 vs E3-4] and severity [S0 or S1] are presented as Kaplan-Meier curves [ Figures 3 and 4] . The cumulative risk for colectomy, hospitalisation, exacerbation, and commencing biologic therapy during follow-up was 18%, 63%, 84%, and 34%, respectively. 
Discussion
In the present study, which describes one of the largest cohorts of paediatric IBD patients stratified according to the Paris classification at diagnosis, we found that in CD patients, complicated behaviour at diagnosis predicted worse long-term outcomes including intestinal resection and early hospitalisation; whereas the isolated colonic phenotype was protective from intestinal resection. In UC patients, severity of disease at diagnosis predicted a detrimental disease course with a significantly increased risk for colectomy, hospitalisation, disease flare, and stepping-up to biologic treatment; however, intriguingly, disease extent was not associated with worse long-term outcome except for the likelihood of receiving biologic treatment. Up until now, only few studies evaluated the predictive properties of the relatively new paediatric modification of the 'veteran' Montreal classification 16 for IBD patients from 2005. Studies evaluating the long-term disease outcome according to the Montreal classification yielded somewhat conflicting results. In CD, although the younger age category [A1] were at increased risk for pan-enteric disease, they were not more likely to have more complicated disease or undergo surgery than older age groups. 17 Ileal location of disease at diagnosis correlated with an increased risk for intestinal resection. 18 In one study, upper gastrointestinal involvement [L4] was predictive of multiple intestinal resections. 19 Complicated behaviour [B2 or B3] at diagnosis conferred a higher risk for subsequent intestinal resection in some of the studies, 19, 20 but not in all. 18 In UC, extensive disease was shown to be consistently associated with increased risk for colectomy. 21, 22 The distribution of patients across the Paris classification categories in the current study was not substantially different from previous paediatric studies performed following the appraisal of the Paris classification. [9] [10] [11] Most of these paediatric studies aimed to assess phenotypic features according to the Paris modification, but did not focus on the long-term outcomes of both diseases. 10, 11 In a recent report of a large paediatric cohort of CD patients from Korea, complicated behaviour and isolated colonic location [L2] at diagnosis were associated with an increased and a decreased risk of intestinal resection, respectively, and in concordance with our findings. 9 As previously demonstrated, we also found an association of L1 location with ASCA positivity, and of L2 location with an increased risk of extraintestinal manifestations. 23, 24 We previously reported an association of perianal disease at diagnosis with early hospitalisation [HR 1.34, p = 0.027] as well as early use of biologic therapy [HR 1.7, p = 0.002], completing the missing component of the survival analysis of the Paris classification for CD. 12 In this previous study, perianal disease was not associated with the other constructs of the Paris classification including age, location, behaviour and growth.
Similar to the findings of Aloi et al., 7 in our cohort we also confirmed that surgical risk [as well as other long-term outcomes] of patients with early onset IBD [< 10 years of age] did not differ from older patients for either CD or UC patients. In a more recent cohort, 25 disease activity did not differ according to age group [very early onset, < 6 vs early onset, 6-10 vs > 10 years] 5 years post diagnosis for either CD or UC. Our findings, together with the few previous paediatric studies which stratified disease outcomes according to age at, [25] [26] [27] strengthen the notion that despite the fact that childhood IBD is more aggressive and complicated compared with adult IBD, 28 early disease onset within the paediatric age group does not confer additional risk for a more severe course.
Even more surprising is the lack of association between growth impairment [G1 phenotype] at diagnosis and worse disease outcomes. Growth impairment was consistently shown to be associated with severity of disease at diagnosis, 29, 30 so it was expected to predict a more aggressive course. It is possible that growth impairment at diagnosis represents an early age of onset [pre-pubertal] which affects growth more profoundly, and not necessarily a more severe disease. Furthermore, paediatric patients with growth failure may be (a) treated more aggressively [we noticed such a trend for early biologic therapy for G1 patients in our cohort, though not reaching statistical significance], thus affecting the natural history of their disease. In this study, we clearly show that the severity of UC at diagnosis, rather than its extent, is a clear predictor of worse disease outcomes including time to colectomy, hospitalisation, disease flare, and stepping-up to biologic therapy. Schechter et al. previously demonstrated that severe disease at 3 months following diagnosis of UC in children predicted early colectomy. 31 It seems that severe disease at diagnosis is also associated with this risk, suggesting that a rapid acceleration in therapy should be considered in order to, potentially, minimise future detrimental outcomes. The association of extensive disease with early biologic therapy could plausibly explain the lack of association between extent and colectomy risk, as more patients with extensive disease were treated with biologic therapy, which may have decreased the surgical rate in these patients.
The cumulative surgical rate of 26% for CD and 18% for UC after a median follow-up of approximately 9 years, reported in this study, is in the lower range of what was demonstrated in previous studies. 9, 10, 20, 32 This plausibly may reflect the relative abundant use of biologic agents (primarily anti-tumour necrosis factor [TNF] agents) in 54% of CD patients and in 35% of UC patients, which is currently the standard of care in severe or complicated disease. Another interesting observation is the perspective of morbidity reflected by the cumulative hospitalisation and exacerbation rates for both diseases. Despite the fact that CD is a pan-enteric disease subjected to complications such as intestinal stenosis, intra-abdominal abscesses, and perianal fistulising disease, still the cumulative exacerbation and hospitalisation rates in UC patients were 84% and 63.5%, respectively. These are much higher than the equivalent rates of 66% and 56% in CD patients. This is another support for the severity of paediatric onset UC as opposed to adult onset disease. 33, 34 Despite the relatively large cohort size, long-term follow-up and comprehensive analysis of outcomes, this study has several limitations. Naturally, the retrospective nature of the study is a major limitation which may bias some of the observations and also limits accurate data collection such as more validated clinical indices, for example the PCDAI. Also, especially for UC, the number of children in this cohort is relatively small and therefore findings may be at risk of type II error. Furthermore, the specific features of the Paris classification in UC patients were compromised because of the merge of E1-2 and E3-4, and possibly by merging UC with IBD-unclassified patients within the same group.
In conclusion, the phenotypic characteristics at presentation in paediatric IBD, defined by the Paris classification, have clear predictive properties. Complicated disease and ileal location at diagnosis predict long-term worse outcomes in CD, whereas severity of disease at diagnosis but not the extent of inflammation is associated with worse outcomes in UC. Despite being a mucosal disease, paediatric onset UC does not carry a diminished long-term morbidity in comparison with CD.
Funding
No funding was secured for this study.
